HC Wainwright & Co. Maintains Buy on Relay Therapeutics, Raises Price Target to $29

Relay Therapeutics, Inc.

Relay Therapeutics, Inc.

RLAY

0.00

HC Wainwright & Co. analyst Robert Burns maintains Relay Therapeutics (NASDAQ: RLAY) with a Buy and raises the price target from $28 to $29.